Paul Capital, TVM, Signet invest €26m in Euro pharma company

Paris-based specialty pharmaceutical company SpePharm will use €10m to fund the acquisition of a Proctor & Gamble product.

Paul Capital Healthcare (PCH), TVM Capital and Signet Healthcare Partners have invested a combined €26 million ($39 million) in Paris-based specialty pharmaceutical company SpePharm.

PCH and TVM have entered into a €10 million revenue interest acquisition financing agreement to fund SpePharm’s acquisition of Dantrium, a product used to treat life-threatening hyperthermia caused by gaseous anesthetics, from Procter & Gamble.  

New York-based Signet has joined PCH and TVM in a €16 million separate financing round to fund the ongoing growth of SpePharm holding. SpePharm’s senior management will also participate in the current equity financing, according to joint statement from the private equity firms and the pharmaceutical company.

SpePharm focuses on acquiring, registering and marketing high medical value specialty medicines for hospital throughout Europe. Seeded in 2006 by TVM and Signet, the company specialises in oncology, critical and supportive care products, and has an established presence in the UK, Germany, Italy, the Benelux and Nordic areas.

New York-based PCH is one of three platforms within Paul Capital, alongside its private equity secondaries and fund of funds units. PCH manages roughly $1.5 billion in commitments.  

Munich-based TVM Capital currently manages roughly $1.26 billion in assets and focuses on venture and growth investments in US and European biotechnology and pharmaceutical companies.